Incredible progress has been made in the field of oncology to help improve the lives of many people affected by cancer. Yet that work is far from done. We believe that much more can and must be done to transform cancer care and patient outcomes.
We are a science-led organization of curious minds dedicated to delivering transformative cancer medicines to the people who need them. Curiosity drives us to discover and develop medicines for several challenging cancers, and patients inspire us to relentlessly pursue scientific breakthroughs that will help make a difference in their lives.
We are leveraging our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR), and focusing our scientific discovery and development with our goal to unleash the potential of several promising approaches in cancer research.
We are exploring oncogenic pathways to grow the number of targeted therapies and expand the uses of our existing targeted therapy.
Learn more about one of our areas of research at clinicaltrials.targeting-met.com.
We’re accelerating the development of current and next-generation immuno-oncology medicines that harness the patient's immune system to help fight cancer.
We’re pioneering research into the multiple pathways involved in DDR with the aim of disrupting the tumor’s ability to repair damage and restoring sensitivity to treatments, making DDR a potential platform for developing new combinations with I-O compounds and other therapies.
Visit WebsiteWe are applying our scientific curiosity to tackle several challenging tumor types in cancer.
Visit PipelineLUNG CANCER
Non-small cell lung cancer is considered the most common type of lung cancer, accounting for 85% of all cases,1 while small cell lung cancer makes up approximately 15%.2 In the US there are more than 230,000 new cases of lung cancer and 130,000 deaths each year.3
MERKEL CELL CARCINOMA
Merkel cell carcinoma is a rare and aggressive form of skin cancer impacting approximately 2,000 people in the United States every year.4
RENAL CELL CARCINOMA
Renal cell carcinoma is the most common type of kidney cancer, accounting for approximately 85% of all malignant kidney tumors.5
UROTHELIAL CARCINOMA
Urothelial carcinoma is a cancer that starts in the urothelial cells that line the inside of the bladder.6 It’s the 6th most common cancer in the United States – with more than 80,000 new cases estimated in 2021.7
BAVENCIO® (avelumab) Injection 20mg/mL
Press Releases
The company today announced it has exercised its option with Abbisko for commercialization of pimicotinib in the U.S. and rest of world.
2025/03/28
Press Releases
Phase III MANEUVER trial of pimicotinib met its primary endpoint, demonstrating significant improvement in objective response rate in TGCT-patients.
2024/11/12
Press Releases
Discontinuation of the Phase III randomized TrilynX study
2024/06/24
1 American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed May 3, 2021.
2 Wang S, et al. Sci Rep. 2017;(1):1339.
3 American Cancer Society. Key Statistics for Lung Cancer. Available at: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Accessed May 3, 2021.
4 American Cancer Society. Key Statistics for Merkel Cell Carcinoma. Available at: https://www.cancer.org/cancer/merkel-cell-skin-cancer/about/key-statistics.html. Accessed May 3, 2021.
5 Cleveland Clinic. Kidney Cancer. Available at: https://my.clevelandclinic.org/health/diseases/9409-kidney-cancer-overview. Accessed May 3, 2021.
6 Cancer.net. Bladder Cancer: Introduction. https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed May 4, 2021.
7 National Cancer Institute. Cancer Stat Facts: Bladder Cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed May 4, 2021.
